Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Virtu Financial LLC

Key Points

• Virtu Financial LLC increased its stake in Halozyme Therapeutics by 110.3%, now holding 13,795 shares valued at approximately $880,000.
• Despite significant institutional investment, CEO Helen Torley sold 20,000 shares amounting to over $1.1 million, indicating a reduction in her ownership stake.
• Following recent analyst coverage, Halozyme Therapeutics has mixed ratings, with a few analysts issuing downgrades while others increased their price targets significantly.

Virtu Financial LLC lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 110.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,795 shares of the biopharmaceutical company's stock after acquiring an additional 7,234 shares during the quarter. Virtu Financial LLC's holdings in Halozyme Therapeutics were worth $880,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at about $29,000. Bessemer Group Inc. lifted its holdings in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares in the last quarter. Park Place Capital Corp lifted its holdings in Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares in the last quarter. UMB Bank n.a. lifted its holdings in Halozyme Therapeutics by 267.4% during the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock valued at $84,000 after buying an additional 960 shares in the last quarter. Finally, CWM LLC lifted its holdings in Halozyme Therapeutics by 46.3% during the 1st quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company's stock valued at $88,000 after buying an additional 438 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Up 2.6%

Shares of NASDAQ HALO traded up $1.73 during trading hours on Friday, hitting $67.27. 1,665,726 shares of the stock were exchanged, compared to its average volume of 1,818,312. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The company has a market cap of $7.87 billion, a PE ratio of 15.39, a PEG ratio of 0.37 and a beta of 1.17. The firm has a fifty day moving average price of $57.06 and a 200-day moving average price of $58.26. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $70.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. Halozyme Therapeutics's revenue was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.91 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $46,598,493.69. This represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 80,000 shares of company stock worth $4,532,600. Corporate insiders own 2.40% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on HALO shares. Leerink Partners lowered shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective for the company. in a report on Tuesday, May 13th. JMP Securities upped their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. Morgan Stanley raised shares of Halozyme Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price target for the stock from $62.00 to $75.00 in a research report on Wednesday, August 6th. Wells Fargo & Company upped their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. Finally, Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $66.56.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.